A lesion arising within the sella turcica that is a prolactin adenoma autonomously overproduces prolactin. Elevated prolactin exerts negative feedback suppression on the hypothalamus, inhibiting the secretion of gonadotropin-releasing hormone (GnRH). With GnRH suppressed, the anterior pituitary fails to synthesize and release follicle-stimulating hormone (FSH) and luteinizing hormone (LH).

Asymptomatic pituitary adenomas are nearly always detected incidentally. Some patients undergo CT scans for headaches; others receive fundus examinations for blurred vision. Another common presentation involves patients with over a year of unsuccessful conception, unremarkable gynecological workups, followed by reproductive endocrinologists ordering serum prolactin testing. A reading exceeding 120 prompts pituitary MRI, which identifies a 6-millimeter microadenoma on the right pituitary gland. Upon receiving the report, patients rarely fixate on the intracranial lesion itself—their primary concern is whether they can still conceive.

The answer is yes. This subtype of infertility carries the most favorable prognosis among all complications of pituitary adenomas.

Mechanism of Infertility

As mentioned above, prolactin adenomas within the sella turcica secrete excessive prolactin. Hyperprolactinemia suppresses hypothalamic GnRH release, halting anterior pituitary FSH and LH production. Without FSH and LH, ovarian ovulation ceases and amenorrhea develops. This pathological cascade resembles a domino effect, triggered by a tiny lesion merely a few millimeters in size. Notably, most patients report minimal subjective discomfort, only mild menstrual irregularity and occasional galactorrhea that they dismiss as trivial, until persistent infertility after many months of trying to conceive leads to diagnosis.

Fortunately, this hormonal cascade is fully reversible.

Prolactin adenomas respond well to oral pharmacotherapy. Dopamine receptor agonists bind to D2 receptors on lactotrophs to directly inhibit prolactin synthesis and secretion. As prolactin levels decline, GnRH secretion resumes, restoring pulsatile FSH and LH release, ovulation, and regular menstruation. These agents also induce tumor shrinkage; follow-up MRI as early as one to two months after treatment initiation often demonstrates regression of the adenoma. For most patients with microadenomas, menstruation and ovulation normalize within three to six months of achieving target prolactin levels, yielding conception rates comparable to the general fertile population. While pregnancy does not occur immediately upon starting medication, successful conception remains a highly realistic outcome.

Not all pituitary adenomas are managed medically. Non-functioning adenomas produce no excess hormones and cause symptoms solely via mass effect compressing normal pituitary parenchyma and impairing overall pituitary function. Such patients require transsphenoidal endoscopic resection to relieve compressive injury. Postoperatively, the hypothalamic-pituitary hormonal axis recovers, restoring fertility. Though treatment pathways differ, both approaches share the same ultimate goal: successful pregnancy.

Management Following Confirmed Pregnancy

Medications for hyperprolactinemia may be discontinued once intrauterine pregnancy is verified via two positive urine pregnancy tests, with no further treatment required throughout gestation. Many patients worry about adenoma regrowth after drug cessation, yet microadenomas have an extremely low risk of significant enlargement during pregnancy, at less than 3%. Patients with macroadenomas require serial visual field testing and periodic MRI surveillance throughout pregnancy, though symptomatic progression remains uncommon. After delivery and the postpartum confinement period, serum prolactin testing guides decisions on resuming medical therapy. Breastfeeding remains fully compatible with this clinical course and is unrestricted.

This pathology also affects male patients, presenting with distinct clinical manifestations: reduced libido, erectile dysfunction, and impaired sperm quality. Workup reveals elevated prolactin and low testosterone, with imaging confirming a pituitary adenoma. Pharmacological suppression of prolactin restores testosterone concentrations, sexual function, and spermatogenesis. One clinic patient conceived with his wife only three months after his prolactin normalized; he had previously planned to pursue in vitro fertilization and expressed disbelief at the successful natural conception during follow-up visits.

A long-term follow-up patient recently returned to clinic with her young child. She recalled asking whether pregnancy would be possible five years prior at her initial diagnosis. Her child, now preschool-aged, ran freely around the consultation room as I drafted lab orders, neither of us needing verbal reflection on her journey. Some questions require no spoken reply—the child standing before us is the definitive answer.

With timely, active treatment, the vast majority of patients can achieve successful pregnancy.